000283081 001__ 283081
000283081 005__ 20251231103633.0
000283081 0247_ $$2doi$$a10.1002/alz70860_105004
000283081 0247_ $$2ISSN$$a1552-5260
000283081 0247_ $$2ISSN$$a1552-5279
000283081 037__ $$aDZNE-2025-01488
000283081 082__ $$a610
000283081 1001_ $$0P:(DE-2719)9001692$$aMarquardt, Jonas$$b0$$eFirst author$$udzne
000283081 1112_ $$aAlzheimer’s Association International Conference$$cToronto$$d2025-07-27 - 2025-07-31$$gAAIC 25$$wCanada
000283081 245__ $$aHippocampal vascularization is associated with greater efficiency during a remote real world wayfinding training in older adults
000283081 260__ $$c2025
000283081 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1767100096_6285
000283081 3367_ $$033$$2EndNote$$aConference Paper
000283081 3367_ $$2BibTeX$$aINPROCEEDINGS
000283081 3367_ $$2DRIVER$$aconferenceObject
000283081 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
000283081 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000283081 3367_ $$2ORCID$$aOTHER
000283081 520__ $$aBackground:Alzheimer's Disease (AD) pathology accumulates early in the medial temporal lobe (MTL), crucial for spatial navigation. As spatial navigation is among the first cognitive functions affected by AD, it may benefit from targeted behavioral interventions. We investigated the potential of a novel smartphone-assisted real-world wayfinding training, tailored for healthy older adults, to improve their spatial abilities and explored associations with hippocampal vascularization and AD biomarkers.Method: 38 cognitively healthy older adults (62–84 years; 18 females) participated in a 3-week navigation training, using our smartphone application “Explore” (Figure 1). Training involved finding several locations displayed on a map in the medical campus area of Magdeburg, Germany, while GPS data were recorded. Pre- and post-training, participants underwent fMRI, performed a pointing task in a virtual campus version, and completed the VWLT. At pre-assessment, AD pathology was characterized by plasma sampling (Abeta1-42/1-40, Ptau217) and [18F]PI-2620 PET in a subsample. Hippocampal vascularization was assessed by 7T angiography. Performance in the virtual pointing task and a map drawing test was compared to a control group (n = 20) who performed a walking task of equal length without a navigational component. Additionally, changes in different mobile wayfinding performance indicators and their associations with AD biomarkers and hippocampal vascularization (i.e., mean distance of hippocampus to surrounding vessels) were examined.Result: Performance in the pointing task and map drawing, but not in the VWLT (p = .321), significantly improved due to the training (all p < .001; Figure 2A C). The control group showed no improvements in navigation. Training benefits were also evident in the mobile data (all p ≤.017; Figure 3A-E). Better wayfinding efficiency was associated with less vessel distance to hippocampus, r=.44, p = .012, and the number of orientation stops was negatively related to pTau217, r=-.38, p = .019 (Figure 3F).Conclusion: We provide evidence that a remotely administered real-world wayfinding training enhances wayfinding abilities and improves spatial memory in older adults. Importantly, hippocampal vascularization may benefit wayfinding efficiency. Higher pTau217 was related to fewer orientation stops during navigation. As a next step, potential mediating effects between vascularization and AD pathology on wayfinding performance will be investigated.
000283081 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283081 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x1
000283081 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000283081 7001_ $$0P:(DE-2719)9000804$$aVockert, Niklas$$b1$$udzne
000283081 7001_ $$0P:(DE-2719)9002133$$aBehrenbruch, Niklas$$b2$$udzne
000283081 7001_ $$0P:(DE-2719)9002320$$aSchumann-Werner, Beate$$b3$$udzne
000283081 7001_ $$0P:(DE-2719)2812346$$aHochkeppler, Anne$$b4$$udzne
000283081 7001_ $$0P:(DE-2719)9001800$$aBuechel, Anna-Therese$$b5
000283081 7001_ $$0P:(DE-2719)9002180$$aMolloy, Eóin N.$$b6
000283081 7001_ $$0P:(DE-2719)9000379$$aSchwarck, Svenja$$b7
000283081 7001_ $$0P:(DE-2719)9002356$$aFischer, Larissa$$b8$$udzne
000283081 7001_ $$0P:(DE-2719)9001517$$aIncesoy, Enise I.$$b9$$udzne
000283081 7001_ $$0P:(DE-2719)2812734$$aGarcia-Garcia, Berta$$b10$$udzne
000283081 7001_ $$0P:(DE-2719)9002178$$aMattern, Hendrik$$b11$$udzne
000283081 7001_ $$0P:(DE-2719)9003591$$aMarcos Morgado, Barbara$$b12$$udzne
000283081 7001_ $$0P:(DE-HGF)0$$aEsselmann, Hermann$$b13
000283081 7001_ $$0P:(DE-HGF)0$$aStephens, Andrew W.$$b14
000283081 7001_ $$0P:(DE-HGF)0$$aSchildan, Andreas$$b15
000283081 7001_ $$0P:(DE-HGF)0$$aBarthel, Henryk$$b16
000283081 7001_ $$0P:(DE-2719)2814810$$aSabri, Osama$$b17$$udzne
000283081 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b18$$udzne
000283081 7001_ $$0P:(DE-2719)2812799$$aKreissl, Michael C.$$b19$$udzne
000283081 7001_ $$0P:(DE-2719)2000005$$aDüzel, Emrah$$b20$$udzne
000283081 7001_ $$0P:(DE-2719)9001179$$aKuehn, Esther$$b21$$udzne
000283081 7001_ $$0P:(DE-2719)2812631$$aSchreiber, Stefanie$$b22$$udzne
000283081 7001_ $$0P:(DE-2719)2811815$$aMaass, Anne$$b23$$udzne
000283081 7001_ $$0P:(DE-2719)2811077$$aDiersch, Nadine$$b24$$eLast author
000283081 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70860_105004$$gVol. 21, no. S6, p. e105004$$nS6$$pe105004$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000283081 8564_ $$uhttps://pub.dzne.de/record/283081/files/DZNE-2025-1488.pdf$$yOpenAccess
000283081 8564_ $$uhttps://pub.dzne.de/record/283081/files/DZNE-2025-1488.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000283081 909CO $$ooai:pub.dzne.de:283081$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000283081 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001692$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000283081 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000804$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000283081 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002133$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000283081 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002320$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000283081 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812346$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000283081 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001800$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000283081 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002180$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000283081 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000379$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000283081 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002356$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000283081 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001517$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000283081 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812734$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000283081 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002178$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000283081 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003591$$aExternal Institute$$b12$$kExtern
000283081 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2814810$$aExternal Institute$$b17$$kExtern
000283081 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b18$$kDZNE
000283081 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812799$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b19$$kDZNE
000283081 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000005$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b20$$kDZNE
000283081 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001179$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b21$$kDZNE
000283081 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812631$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b22$$kDZNE
000283081 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811815$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b23$$kDZNE
000283081 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811077$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b24$$kDZNE
000283081 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283081 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x1
000283081 9141_ $$y2025
000283081 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283081 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283081 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000283081 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283081 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283081 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283081 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283081 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283081 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000283081 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283081 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283081 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283081 9201_ $$0I:(DE-2719)1311001$$kAG Maaß$$lMultimodal Neuroimaging$$x0
000283081 9201_ $$0I:(DE-2719)5000006$$kAG Düzel$$lClinical Neurophysiology and Memory$$x1
000283081 9201_ $$0I:(DE-2719)1310010$$kAG Schreiber$$lMixed Cerebral Pathologies and Cognitive Aging$$x2
000283081 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lMolecular biomarkers for predictive diagnostics of neurodegenerative diseases$$x3
000283081 9201_ $$0I:(DE-2719)1340016$$kCore MR PET$$lCore MR PET$$x4
000283081 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x5
000283081 980__ $$aabstract
000283081 980__ $$aVDB
000283081 980__ $$aUNRESTRICTED
000283081 980__ $$ajournal
000283081 980__ $$aI:(DE-2719)1311001
000283081 980__ $$aI:(DE-2719)5000006
000283081 980__ $$aI:(DE-2719)1310010
000283081 980__ $$aI:(DE-2719)1410006
000283081 980__ $$aI:(DE-2719)1340016
000283081 980__ $$aI:(DE-2719)1210000
000283081 9801_ $$aFullTexts